July 15, 2016 08:53 AM EDTUpdated July 18, 06:58 PM
R&D

FDA re­view de­tails sui­cides, car­dio risks linked to Valeant’s $100M drug bro­dalum­ab

John Carroll

Editor & Founder

At one point not long ago, As­traZeneca ex­ecs thought their IL-17 pso­ri­a­sis drug bro­dalum­ab could earn up to $1.5 bil­lion in an­nu­al sales. But af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times